Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

JUN 12, 2013 - Benzinga

A Must Read - Share

RBC Says Amgen's AMG-386 Will Need to See Increases in Overall Survival Benefits Before FDA Approval

Amgen's (NASDAQ: AMGN) ovarian cancer drug AMG-386 will need to show palpable increases in overall survival benefits in order to gain FDA approval, according to RBC analyst Michael Yee in a research note from earlier. Investors in Amgen are responding negatively to news a study on AMG-386 met its primary endpoint.

Tags: RBC Says Amgen's AMG-386 Will Need to See Increases in Overall Survival Benefits Before FDA Approval,  Amgen Latest News